Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study

• Published in: Ophthalmology and therapy Vol. 10; no. 3; pp. 565 - 580
• Main Authors: Kramer, Michal, Brichova, Michaela, Tugal-Tutkun, Ilknur, Panchenko, Mykola, Gormezano, Natali, Koenigsbauer, Franziska, Franco, Pablo, Muccioli, Cristina, Hasanreisoglu, Murat
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.09.2021
• Subjects: Internal Medicine; Medicine; Medicine & Public Health; Ophthalmology; Original Research; Immunosuppressants; Patient-reported outcomes; Disease characteristics; Noninfectious uveitis; Corticosteroid disease burden
• ISSN: 2193-8245; 2193-6528
• DOI: 10.1007/s40123-021-00351-4

Introduction The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available. Methods This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records. Results Of 565 patients, 58.8% were female, and the mean age was 41.3 years; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts. Conclusions Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies.